Drug intelligence / Profile preview

PVS-10200

Development stage: Phase 2
Lead developer: Takeda
Modality: Cell Therapies
Administration: Percutaneous, Parenteral

Overview

PVS-10200 is an allogeneic endothelial cell-based therapy developed for the prevention of restenosis in patients with peripheral artery disease (PAD) undergoing percutaneous transluminal angioplasty and stent placement. The therapy consists of allogeneic endothelial cells designed to restore vascular homeostasis and inhibit the inflammatory and proliferative processes that lead to vessel re-narrowing after intervention. Originally developed by Pervasis Therapeutics, the program was acquired by Shire and later transitioned to Takeda. It was evaluated in the Phase 1/2 TRIUMPH study, where it was delivered as a single injection following minimally invasive peripheral revascularization.

Other names: PVS-10200PVS10200PVS 10200

Beyond the preview

Go deeper on PVS-10200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PVS-10200.

Explore the full profile